Plus Therapeutics (PSTV) Competitors $0.68 -0.02 (-2.90%) Closing price 04:00 PM EasternExtended Trading$0.67 0.00 (-0.46%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PSTV vs. SMTI, OM, MGRM, SI, INGN, TLSI, CVRX, NNOX, CV, and INFUShould you be buying Plus Therapeutics stock or one of its competitors? The main competitors of Plus Therapeutics include Sanara MedTech (SMTI), Outset Medical (OM), Monogram Orthopaedics (MGRM), Shoulder Innovations (SI), Inogen (INGN), TriSalus Life Sciences (TLSI), CVRx (CVRX), Nano-X Imaging (NNOX), CapsoVision (CV), and InfuSystem (INFU). These companies are all part of the "medical equipment" industry. Plus Therapeutics vs. Its Competitors Sanara MedTech Outset Medical Monogram Orthopaedics Shoulder Innovations Inogen TriSalus Life Sciences CVRx Nano-X Imaging CapsoVision InfuSystem Sanara MedTech (NASDAQ:SMTI) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends. Does the media prefer SMTI or PSTV? In the previous week, Plus Therapeutics had 3 more articles in the media than Sanara MedTech. MarketBeat recorded 6 mentions for Plus Therapeutics and 3 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 0.83 beat Plus Therapeutics' score of 0.74 indicating that Sanara MedTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanara MedTech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Plus Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is SMTI or PSTV more profitable? Sanara MedTech has a net margin of -10.22% compared to Plus Therapeutics' net margin of -357.85%. Plus Therapeutics' return on equity of 0.00% beat Sanara MedTech's return on equity.Company Net Margins Return on Equity Return on Assets Sanara MedTech-10.22% -26.43% -10.69% Plus Therapeutics -357.85%N/A -117.72% Which has preferable valuation and earnings, SMTI or PSTV? Sanara MedTech has higher revenue and earnings than Plus Therapeutics. Sanara MedTech is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSanara MedTech$86.67M3.08-$9.66M-$1.16-25.86Plus Therapeutics$5.82M11.55-$12.98M-$2.24-0.30 Which has more risk & volatility, SMTI or PSTV? Sanara MedTech has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, Plus Therapeutics has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Do analysts rate SMTI or PSTV? Sanara MedTech currently has a consensus price target of $50.00, suggesting a potential upside of 66.67%. Plus Therapeutics has a consensus price target of $8.00, suggesting a potential upside of 1,081.51%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Plus Therapeutics is more favorable than Sanara MedTech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sanara MedTech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Plus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83 Do insiders and institutionals hold more shares of SMTI or PSTV? 8.1% of Sanara MedTech shares are owned by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are owned by institutional investors. 42.6% of Sanara MedTech shares are owned by insiders. Comparatively, 0.8% of Plus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummarySanara MedTech beats Plus Therapeutics on 9 of the 17 factors compared between the two stocks. Get Plus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PSTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PSTV vs. The Competition Export to ExcelMetricPlus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$69.22M$2.61B$6.05B$10.30BDividend YieldN/A57.78%5.73%4.82%P/E Ratio-0.3022.5785.3127.10Price / Sales11.55755.26601.46133.29Price / CashN/A26.3325.7730.18Price / Book-0.455.3512.676.69Net Income-$12.98M$33.06M$3.32B$276.55M7 Day Performance-23.88%0.94%-0.44%-1.14%1 Month Performance51.37%9.75%8.72%6.50%1 Year Performance-50.58%-0.52%75.69%33.95% Plus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PSTVPlus Therapeutics3.7246 of 5 stars$0.68-2.9%$8.00+1,081.5%-49.1%$69.22M$5.82M-0.3020SMTISanara MedTech2.399 of 5 stars$31.26+0.2%$50.00+59.9%-9.4%$277.66M$86.67M-26.9560High Trading VolumeOMOutset Medical1.7994 of 5 stars$14.88+2.7%$24.67+65.8%+37.3%$257.43M$113.69M-0.73520News CoverageGap UpHigh Trading VolumeMGRMMonogram Orthopaedics0.9021 of 5 stars$6.00-1.8%$5.40-10.0%N/A$248.26M$370K-12.0028Positive NewsHigh Trading VolumeSIShoulder Innovations2.9578 of 5 stars$13.21+8.4%$19.60+48.4%N/A$248.19MN/A-0.4461Analyst UpgradeINGNInogen3.8914 of 5 stars$8.43-2.5%$11.00+30.5%-9.2%$233.90M$335.70M-7.951,030TLSITriSalus Life Sciences2.536 of 5 stars$4.63+0.2%$10.90+135.4%+1.9%$230.39M$29.43M-3.92106CVRXCVRx2.6416 of 5 stars$8.73+0.2%$14.00+60.4%+19.7%$227.78M$51.29M-4.16160NNOXNano-X Imaging2.6004 of 5 stars$4.13+5.1%$8.50+105.8%-35.0%$227.07M$11.28M-4.59190News CoveragePositive NewsCVCapsoVisionN/A$4.57-4.6%$5.50+20.4%N/A$224.05MN/A0.0090INFUInfuSystem4.4446 of 5 stars$10.50+1.4%$13.50+28.6%+33.2%$214.47M$139.89M175.03410Positive News Related Companies and Tools Related Companies Sanara MedTech Competitors Outset Medical Competitors Monogram Orthopaedics Competitors Shoulder Innovations Competitors Inogen Competitors TriSalus Life Sciences Competitors CVRx Competitors Nano-X Imaging Competitors CapsoVision Competitors InfuSystem Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PSTV) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Plus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Plus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
